Salarius Pharmaceuticals Stock Surges 110% Amid Public Offering Plans

Salarius Pharmaceuticals (SLRX) shares more than doubled in value Tuesday following the clinical-stage biotech firm''s announcement of a planned public offering. While SEC filings lack specifics on share quantity or pricing, the offering includes pre-funded warrants for investors whose stakes WOULD exceed 4.99% post-transaction.

The Nasdaq Hearings Panel granted SLRX a compliance extension, providing breathing room to meet listing requirements. Trading volume exploded to 26.6 million shares - 740x the three-month average - as the stock erased most of its 66% year-to-date decline in a single session.

TipRanks'' AI analyst Spark maintains an Underperform rating on SLRX, citing financial instability concerns. The absence of Wall Street coverage leaves the AI model as one of few formal evaluations available to investors navigating this volatile biotech play.